Industry wants FDA to use its benefit-risk assessment framework to facilitate agency/sponsor discussions during NDA reviews and drug development, not just as a means to explain the agency’s thinking in approving a drug.
The framework, unveiled in March, allows drug reviewers to list the evidence and uncertainties surrounding five decision factors...